Medication info
Entiome Tablets 20 Milligrams (Esomeprazole Magnesium Hydrate)

Entiome Tablets 20 Milligrams (Esomeprazole Magnesium Hydrate)

Prescription medicationTabletOral · Intravenous injection
Ingredient · strength
Esomeprazole Magnesium Dihydrate›21.69mg / 1 tablet
Manufacturer / importer
Selbion Co., Ltd.
Appearance
Pink round film-coated tablets
Packaging
28 tablets (14 tablets/Alu-Alu * 2)
Approval status
Active

MFDS item code 201907046 · Approved 2019.10.04 · Insurance code 055800300

Summary

Main use
Treatment and prevention of reflux and Zollinger-Ellison syndrome, ulcers (eradication therapy and prevention of rebleeding), and gastrointestinal disorders caused by anti-inflammatory analgesics
Who uses it
Adults · Children
Adult dosage
This medicine should be swallowed with a liquid such as water and should not be chewed or crushed. 1. Adults 1) Gastroesophageal reflux disease (GERD). - Treatment of erosive reflux esophagitis: Administer 40 mg once daily for 4 weeks. Patients whose esophagitis has not healed or whose symptoms persist may take it for an additional 4 weeks. - Long-term maintenance therapy to prevent recurrence in patients with esophagitis: 20 mg once daily - Symptomatic treatment of gastroesophageal reflux disease without esophagitis: · 20 mg once daily. If symptoms are not controlled after 4 weeks, further evaluation is necessary. · Once symptoms have resolved, subsequent recurrent symptoms are controlled by administering 20 mg once daily. · In adults, 20 mg may be administered once daily as needed. As-needed administration to control recurrent symptoms is not recommended for patients at high risk of gastric and duodenal ulcers due to nonsteroidal anti-inflammatory drug use. 2) Combination antibiotic therapy for Helicobacter pylori eradication Administer this medicine 20 mg with amoxicillin 1 g and clarithromycin 500 mg twice daily for 7 days. 3) Short-term treatment of upper gastrointestinal symptoms (pain, discomfort, burning sensation) associated with nonsteroidal anti-inflammatory drug use (nonselective or selective COX-2 inhibitors) - 20 mg once daily. If symptoms are not controlled after 4 weeks, further evaluation is necessary. Clinical studies exceeding 4 weeks have not been conducted. 4) Patients requiring continuous nonsteroidal anti-inflammatory drug therapy - Treatment of gastric ulcers associated with nonsteroidal anti-inflammatory drug use: 20 mg once daily. The treatment duration is 4∼8 weeks. - Prevention of gastric and duodenal ulcers associated with nonsteroidal anti-inflammatory drug use: 20 mg once daily. 5) Treatment of Zollinger-Ellison syndrome The recommended initial dose is 40 mg twice daily. The subsequent dose should be adjusted for each patient, and treatment should continue while clinical symptoms are present. Clinical data indicate that most patients can be controlled with a dose of 80 ∼ 160 mg per day. Doses above 80 mg per day should be divided and taken twice daily. 6) Maintenance therapy following intravenous induction of prevention of rebleeding due to gastric or duodenal ulcers Administer 40 mg once daily for 4 weeks following intravenous induction of prevention of rebleeding due to gastric or duodenal ulcers. 4. Renal impairment No dose adjustment is necessary. Since there is limited experience in patients with severe renal impairment, administer with caution. 5. Hepatic impairment No dose adjustment is necessary in patients with mild to moderate hepatic impairment. In patients with severe hepatic impairment, the dose of this medicine should not exceed 20 mg. 6. Elderly patients No dose adjustment is necessary.
Children's dosage
Adolescents aged 12 years and older - Treatment of erosive reflux esophagitis: Administer 40 mg once daily for 4 weeks. Patients whose esophagitis has not healed or whose symptoms persist may take it for an additional 4 weeks. - Symptomatic treatment of gastroesophageal reflux disease without esophagitis: 20 mg once daily. If symptoms are not controlled after 4 weeks, further evaluation is necessary. - Symptomatic treatment of gastroesophageal reflux disease without esophagitis: Once symptoms have resolved, subsequent recurrent symptoms are controlled by administering 20 mg once daily. Children under 12 years of age There is no experience with administration of this medicine to children under 12 years of age.

Ingredients

Manufacturer
Selbion Co., Ltd.

Efficacy & effects

Treatment and prevention of reflux and Zollinger-Ellison syndrome, ulcers (eradication therapy and prevention of rebleeding), and gastrointestinal disorders caused by anti-inflammatory analgesics

  • Gastroesophageal reflux disease
  • erosive reflux esophagitis
  • esophagitis
  • duodenal ulcers positive for Helicobacter pylori
  • peptic ulcer
  • upper gastrointestinal pain
  • upper gastrointestinal discomfort
  • upper gastrointestinal burning sensation
  • gastric ulcers related to the use of non-steroidal anti-inflammatory drugs
  • duodenal ulcers related to the use of non-steroidal anti-inflammatory drugs.
View approved original text

This medication is used to treat gastroesophageal reflux disease and erosive reflux esophagitis and is effective for long-term maintenance therapy to prevent recurrence. It is also used in combination with antibiotics for the treatment of duodenal ulcers and peptic ulcers caused by Helicobacter pylori infection. It provides short-term relief of upper gastrointestinal symptoms caused by the use of non-steroidal anti-inflammatory drugs and helps in the treatment and prevention of gastric and duodenal ulcers in patients requiring long-term analgesic therapy. It is also applicable in the treatment of Zollinger-Ellison syndrome and is used in maintenance therapy for the prevention of gastric or duodenal ulcer rebleeding after intravenous treatment. Overall, it is effectively used for the treatment of various gastrointestinal-related diseases and symptom relief.

Dosage and Administration

Adult dosage

This medicine should be swallowed with a liquid such as water and should not be chewed or crushed. 1. Adults 1) Gastroesophageal reflux disease (GERD). - Treatment of erosive reflux esophagitis: Administer 40 mg once daily for 4 weeks. Patients whose esophagitis has not healed or whose symptoms persist may take it for an additional 4 weeks. - Long-term maintenance therapy to prevent recurrence in patients with esophagitis: 20 mg once daily - Symptomatic treatment of gastroesophageal reflux disease without esophagitis: · 20 mg once daily. If symptoms are not controlled after 4 weeks, further evaluation is necessary. · Once symptoms have resolved, subsequent recurrent symptoms are controlled by administering 20 mg once daily. · In adults, 20 mg may be administered once daily as needed. As-needed administration to control recurrent symptoms is not recommended for patients at high risk of gastric and duodenal ulcers due to nonsteroidal anti-inflammatory drug use. 2) Combination antibiotic therapy for Helicobacter pylori eradication Administer this medicine 20 mg with amoxicillin 1 g and clarithromycin 500 mg twice daily for 7 days. 3) Short-term treatment of upper gastrointestinal symptoms (pain, discomfort, burning sensation) associated with nonsteroidal anti-inflammatory drug use (nonselective or selective COX-2 inhibitors) - 20 mg once daily. If symptoms are not controlled after 4 weeks, further evaluation is necessary. Clinical studies exceeding 4 weeks have not been conducted. 4) Patients requiring continuous nonsteroidal anti-inflammatory drug therapy - Treatment of gastric ulcers associated with nonsteroidal anti-inflammatory drug use: 20 mg once daily. The treatment duration is 4∼8 weeks. - Prevention of gastric and duodenal ulcers associated with nonsteroidal anti-inflammatory drug use: 20 mg once daily. 5) Treatment of Zollinger-Ellison syndrome The recommended initial dose is 40 mg twice daily. The subsequent dose should be adjusted for each patient, and treatment should continue while clinical symptoms are present. Clinical data indicate that most patients can be controlled with a dose of 80 ∼ 160 mg per day. Doses above 80 mg per day should be divided and taken twice daily. 6) Maintenance therapy following intravenous induction of prevention of rebleeding due to gastric or duodenal ulcers Administer 40 mg once daily for 4 weeks following intravenous induction of prevention of rebleeding due to gastric or duodenal ulcers. 4. Renal impairment No dose adjustment is necessary. Since there is limited experience in patients with severe renal impairment, administer with caution. 5. Hepatic impairment No dose adjustment is necessary in patients with mild to moderate hepatic impairment. In patients with severe hepatic impairment, the dose of this medicine should not exceed 20 mg. 6. Elderly patients No dose adjustment is necessary.

Children's dosage

Adolescents aged 12 years and older - Treatment of erosive reflux esophagitis: Administer 40 mg once daily for 4 weeks. Patients whose esophagitis has not healed or whose symptoms persist may take it for an additional 4 weeks. - Symptomatic treatment of gastroesophageal reflux disease without esophagitis: 20 mg once daily. If symptoms are not controlled after 4 weeks, further evaluation is necessary. - Symptomatic treatment of gastroesophageal reflux disease without esophagitis: Once symptoms have resolved, subsequent recurrent symptoms are controlled by administering 20 mg once daily. Children under 12 years of age There is no experience with administration of this medicine to children under 12 years of age.

Precautions

This medication should not be administered to individuals with allergies to certain medications or components. In particular, patients allergic to penicillin-based or macrolide antibiotics or those taking specific cardiac-related medications should not use this drug. Additionally, individuals with a history of myocardial infarction or those who are breastfeeding should not take this medication. Various side effects may occur while using this drug; if symptoms such as headache, dizziness, abdominal pain, or skin rash occur, immediate consultation with a healthcare professional is recommended. Regular monitoring is required for long-term use, especially for hypomagnesemia with low magnesium levels. This drug may interact with other medications; if you are taking other drugs, you must inform your doctor or pharmacist. Caution is required during pregnancy, and breastfeeding individuals should avoid taking this medication. There is no specific antidote for overdose, and appropriate treatment should be received based on symptoms. Store out of reach of children and do not transfer to another container.

Side effects

Leukopenia, thrombocytopenia, agranulocytosis, pancytopenia, fever, angioedema, anaphylactic reactions, shock, peripheral edema, hyponatremia, hypomagnesemia, insomnia, anxiety, mental confusion, depression, aggression, hallucinations, headache, dizziness, sensory disturbances, drowsiness, taste disorders, blurred vision, bronchospasm, pancreatitis, abdominal pain, constipation, diarrhea, abdominal bloating, nausea, vomiting, dry mouth, stomatitis, gastrointestinal candidiasis, microscopic colitis, elevated liver enzymes, hepatitis, liver failure, encephalopathy, dermatitis, itching, rash, urticaria, hair loss, photosensitivity, erythema multiforme, mucous membrane syndrome, Stevens-Johnson syndrome, toxic epidermal necrolysis, Riel syndrome, acute generalized pustular psoriasis, eosinophilia, systemic symptoms accompanying drug reactions, fractures, arthralgia, myalgia, muscle weakness, interstitial nephritis, gynecomastia, asthenia, increased sweating, Clostridium difficile-associated diarrhea, abdominal distension, allergic reactions, back pain, chest pain, retrosternal pain, facial edema, facial flushing, fatigue, fever, influenza-like symptoms, generalized edema, leg edema, lethargy, pain, stiffness, peripheral edema, flushing, hypertension, tachycardia, goiter, irritable bowel syndrome, worsened constipation, dyspepsia, dysphagia, gastrointestinal malformation, epigastric pain, belching, esophageal disorders, frequent bowel movements, gastroenteritis, gastrointestinal bleeding, hiccups, melena, oral disorders, pharyngeal disorders, rectal disorders, gastrointestinal symptoms, increased serum gastrin, tongue disorders, tongue swelling, ulcerative stomatitis, vomiting, earache, tinnitus, anemia, hypopigmented anemia, cervical lymphadenopathy, nosebleed, leukocytosis, leukopenia, thrombocytopenia, hyperbilirubinemia, abnormal liver function, increased ALT, increased AST, diabetes, hyperuricemia, increased ALP, polydipsia, vitamin B12 deficiency, weight gain, weight loss, exacerbated arthritis, arthropathy, convulsions, fibromyalgia syndrome, hernia, rheumatoid polymyalgia, arthralgia, loss of appetite, apathy, increased appetite, confusion, exacerbated depression, hypertonia, anxiety, sensory loss, erectile dysfunction, insomnia, migraine, aggravated migraine, sleep disorders, tremors, dizziness, visual field defects, sensory disturbances, drowsiness, dysmenorrhea, menstrual disorders, vaginitis, aggravated asthma, cough, dyspnea, laryngeal edema, pharyngitis, rhinitis, sinusitis, acne, anal itching, rash, erythematous rash, papular rash, angioedema, dermatitis, itching, urticaria, increased sweating, otitis media, abnormal olfaction, taste loss, taste disorientation, urinary abnormalities, albuminuria, cystitis, dysuria, fungal infections, hematuria, urination frequency, candidiasis, genital candidiasis, polyuria, conjunctivitis, visual disturbances, duodenitis, esophagitis, esophageal stricture, esophageal ulcers, esophageal varices, gastric ulcers, gastritis, benign polyps, nodules, Barrett's esophagus, mucosal discoloration, hernia, systemic lupus erythematosus, cutaneous lupus erythematosus, gastric fundic gland polyps, hypocalcemia, hypokalemia, rhabdomyolysis

Not everyone experiences these, and they can vary from person to person.

Storage

This drug should be stored in a tightly closed container to prevent air or moisture ingress. The best storage temperature is at room temperature between 1°C to 30°C.

Appearance and packaging

Appearance

Pink round film-coated tablets

Package unit

28 tablets (14 tablets/Alu-Alu * 2)

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.